Showing content from https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Nagaland below:
COVID-19 pandemic in Nagaland - Wikipedia
From Wikipedia, the free encyclopedia
Ongoing COVID-19 viral pandemic in Nagaland
The COVID-19 pandemic reached the state of Nagaland on 22 May 2020, with its first case confirmed on 25 May 2020.[1] Officially, Nagaland is the last of the northeastern states after Sikkim to report COVID-19 positive cases.
On 22 April, a 33-year-old trader based in Dimapur had tested positive in Gauhati Medical College and Hospital (GMCH).
The man had been admitted to a private hospital in Dimapur for treatment but the hospital referred him to the GMCH as the State did not have testing facilities at that point of time. He tested positive hours after he was shifted in an ambulance.
- The first special train carrying over 1469 people, who were stranded in Chennai, reached Dimapur at around 6:20 pm on 22 May. The returnees, mostly students and migrant workers, had started their journey from Chennai on 19 May.[2]
- On 25 May, the Nagaland state Department of Health and Family Welfare reported the first official cases in the state — three people – two men and a woman – who returned from Chennai on 22 May tested positive for the novel coronavirus.[3]
- As of 26 June, the total number of cases in Nagaland was 371, including 209 active cases and 162 recoveries.[4]
On 20 July, total number of cases in Nagaland crossed 1000 mark.[5]
- As of 1 September, the total number of cases in Nagaland was 4003, including 794 active cases and 3191 recoveries. Eight people died from the virus.[4]
- On 12 September, Nagaland's total covid cases crossed 5000 mark.[6]
- As of 28 September, the total number of cases was 5957, including 1002 active cases, 4897 recoveries and 12 deaths.[4]
- As of 4 October, the total number of cases in Nagaland is 6552, including 1221 active cases and 5263 recoveries and 12 deaths.[4]
- As of November 13, the total number of cases in Nagaland is 9638, including 727 active cases and 8859 recoveries and 52 deaths.[4]
- On 17 November, Nagaland passed a grim milestone of 10000 total covid cases.[7]
- As of November 23, the total number of cases in Nagaland is 10744, including 1442 active cases, 9241 recoveries and 61 deaths.[4]
- As of December 5, the total number of cases in Nagaland is 11305, including 481 active cases, 10759 recoveries and 65 deaths.[4]
- As of January 21, the total number of cases in Nagaland is 11928, including 107 active cases, 11733 recoveries and 88 deaths.[4]
- As of 8 February, the total number of cases in Nagaland was 12009, including 84 active cases, 11837 recoveries and 88 deaths.[4]
- As of 16 February, the total number of cases was 12039, including 41 active cases, 11908 recoveries and 90 deaths.[4]
- As of 6 March, the total number of cases in Nagaland was 12058, including 15 active cases, 11952 recoveries and 91 deaths.[4]
- As of 26 May, the total number of cases in Nagaland was 14313, including 4923 active cases, 14929 recoveries and 327 deaths.[4]
Total confirmed cases, active cases, recoveries and deaths[edit]
Total confirmed cases Active Cases Recoveries Deaths
COVID-19 vaccines with approval for emergency or conditional usage[edit] Union Minister for Health & Family Welfare, Dr. Harsh Vardhan visiting the GTB Hospital, Shahdara to review the preparedness of Dry Run of COVID-19 vaccine, in Delhi on January 02, 2021.
Covishield
On January 1, 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca's COVID-19 vaccine AZD1222 (marketed as Covishield).[8] Covishield is developed by the University of Oxford and its spin-out company, Vaccitech.[9] It's a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf life of at least six months.
Covaxin
On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.[10]
COVID-19 pandemic
Timeline Pre-pandemic
2020
2021
2022
2023
Locations Africa
Northern
Eastern
Southern
Central
Western
Asia Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America Atlantic
Canada
Caribbean Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Impact Culture and
entertainment Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines Topics
Authorized DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Variants Specific
General
Institutions
Hospitals and
medical clinics Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials WHO
By location
Others
List of deaths due to COVID-19
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
COVID-19 pandemic in India
Topics
Government response
Incidents
Locations States
Union territories
Legal framework
Agencies and
institutes Administration
Research
and testing Public
Private
Vaccines
Others
Officials Union government
State governments
Agency executives
- Sujeet Kumar Singh (Director, NCDC)
- Balram Bhargava (Director General, ICMR)
- Shanta Dutta (Director, NICED)
- Manoj V. Murhekar (Director, NIE)
- Priya Abraham (Director, NIV)
- V. G. Somani (Drug Controller General)
- Shekhar C. Mande (Director, CSIR)
- Tapas Kumar Kundu (Director, CDRI)
- Rakesh Mishra (Director, CCMB)
- Samit Chattopadhyay (Director, IICB)
- S. Chandrasekhar (Director, IICT)
- Ram A. Vishwakarma (Director, IIIM)
- Sanjeev Khosla (Director, IIMT)
- Anurag Agrawal (Director, IGIB)
- Ashwini Kumar Nangia (Director, NCL)
- D. K. Aswal (Chairman, NABL)
- G. V. K. Reddy (Chairman, GVK EMRI)
- R. K. Jain (Secretary General, IRCS)
COVID-19 portal
RetroSearch is an open source project built by @garambo
| Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4